Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 18 Oct 2017 Status changed from completed to discontinued.
- 02 Mar 2017 Status changed from active, no longer recruiting to completed.
- 21 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.